The JAK inhibitor ruxolitinib could improve the treatment of chronic myeloid leukaemia (CML), a European conference has been told.
A phase 2 trial including the drug alongside standard treatment found an increase in the proportion of patients with...
5 months ago
During National Pathology Week, the BSH, in collaboration with the Limbic, hosted daily webinars on topics involving the laboratory/clinical interface. Delivered by scientists and physicians, they highlighted the importance of multidisciplinary te...
3 months ago
